Tango Therapeutics, Inc. Deferred Tax Assets, Deferred Income
Tango Therapeutics, Inc. (TNGX) had Deferred Tax Assets, Deferred Income of $17.03 million as of 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsDeferredIncome · last filed 2026-03-05
- 2024-12-31: Deferred Tax Assets, Deferred Income $17.03M.
- 2023-12-31: Deferred Tax Assets, Deferred Income $24.64M.
- 2022-12-31: Deferred Tax Assets, Deferred Income $31.63M.
- 2021-12-31: Deferred Tax Assets, Deferred Income $34.63M.
| Period end | Deferred Tax Assets, Deferred Income |
|---|---|
| 2024-12-31 | $17.03M 10-K · filed 2026-03-05 |
| 2023-12-31 | $24.64M 10-K · filed 2025-02-27 |
| 2022-12-31 | $31.63M 10-K · filed 2024-03-18 |
| 2021-12-31 | $34.63M 10-K · filed 2023-03-27 |
| 2020-12-31 | $11.89M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |